Skip to main content

The RheumNow Week in Review – 31 March 2017

Mar 31, 2017 4:39 pm

Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:

Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.

  1. Adaptive immunity evolved 450 mill yrs ago, in jawless hagfish & lampreys expressing VLR receptors & Ag specific resp. Dr Max Cooper @ #ATT2017
  2. Dr S Raychaudhuri shows position 13 of HLA-DRB1 accounts for ~90% risk for rheumatoid arthritis #ATT2017
  3. Rheumatic Paraneoplastic syndromes seen w/ Clubbing (HOA), polyarthritis, PM/DM, palmar fasciitis, panniculitis, vasculitis, oncogenic osteomalacia #TargetedTherapies
  4. CAPRA-2 Study showed Pred 5 mg qd had no increase in infections in RA pts on DMARDs. Dr. WInthrop at #ATT2017
  5. Dr WInthrop #ATT2017 greatest infection risk w/ steroids >15mg/d; BUT Pred>5 incr risk in dose dependent manner, moreso in sicker/active pts
  6. HBV testing is very low in RA; 15k US & 46k Taiwan pts studied; US HBV testing=20.3% & Taiwan=24.5%; incr over time
  7. FDA approves anti-CD20 Ocrelizumab for relapsing, primary progr Multiple sclerosis based on OPERA 1,2, Octavius RCTs
  8. EMA approves Xeljanz (tofacitinib) use in the EU; for mod-severe RA; dose 5 mg bid in combo or as monoRx. .
  9. TNF Inhibitor Induced Psoriasis 
  10. Biologics Do Not Increase Melanoma Risk  
  11. Steroids, DMARDs and Biologics have Same Low Risk of Infection During Pregnancy
  12. Alcohol Use During Methotrexate Studied  
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.